These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9472847)

  • 1. Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer's disease.
    Grothe DR; Piscitelli SC; Dukoff R; Fullerton T; Sunderland T; Molchan SE
    J Clin Psychopharmacol; 1998 Feb; 18(1):78-81. PubMed ID: 9472847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of drugs for Alzheimer's disease.
    Parnetti L
    Clin Pharmacokinet; 1995 Aug; 29(2):110-29. PubMed ID: 7586900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy.
    Laine K; Palovaara S; Tapanainen P; Manninen P
    Clin Pharmacol Ther; 1999 Dec; 66(6):602-8. PubMed ID: 10613616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
    Roberts CJ; Ford JM; Truman CA; Scott M; Mäkelä PM; Wilcock GK
    Eur J Clin Pharmacol; 1998; 54(9-10):721-4. PubMed ID: 9923574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
    Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
    Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WITHDRAWN: Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic studies of cholinesterase inhibitors.
    Johansson M; Nordberg A
    Acta Neurol Scand Suppl; 1993; 149():22-5. PubMed ID: 8128833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy.
    Valis M; Masopust J; Vysata O; Hort J; Dolezal R; Tomek J; Misik J; Kuca K; Karasova JZ
    Neurotox Res; 2017 Jan; 31(1):162-168. PubMed ID: 27718143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.
    Lou G; Montgomery PR; Sitar DS
    J Psychiatry Neurosci; 1996 Nov; 21(5):334-9. PubMed ID: 8973053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease.
    Cutler NR; Sedman AJ; Prior P; Underwood BA; Selen A; Balogh L; Kinkel AW; Gracon SI; Gamzu ER
    Psychopharmacol Bull; 1990; 26(2):231-4. PubMed ID: 2236461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.
    Ahlin A; Hassan M; Junthé T; Nybäck H
    Int Clin Psychopharmacol; 1994; 9(4):263-70. PubMed ID: 7868848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
    Schneider LS; Farlow MR; Henderson VW; Pogoda JM
    Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients.
    Johansson M; Hellström-Lindahl E; Nordberg A
    Dementia; 1996; 7(2):111-7. PubMed ID: 8866685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine.
    Basun H; Nilsberth C; Eckman C; Lannfelt L; Younkin S
    Dement Geriatr Cogn Disord; 2002; 14(3):156-60. PubMed ID: 12218259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease.
    Ford JM; Truman CA; Wilcock GK; Roberts CJ
    Clin Pharmacol Ther; 1993 Jun; 53(6):691-5. PubMed ID: 8513661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.
    Farlow MR; Lahiri DK; Poirier J; Davignon J; Schneider L; Hui SL
    Neurology; 1998 Mar; 50(3):669-77. PubMed ID: 9521254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
    Gutzmann H; Kühl KP; Hadler D; Rapp MA
    Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.
    Cutler NR; Polinsky RJ; Sramek JJ; Enz A; Jhee SS; Mancione L; Hourani J; Zolnouni P
    Acta Neurol Scand; 1998 Apr; 97(4):244-50. PubMed ID: 9576639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.